Survey of dpp-4 enzyme inhibitors on type 2 diabetes patients treated as outpatients at Can Tho central general hospital

Abstract

Type 2 diabetic is a common stituation. Dipeptidyl peptidase-4 inhibitor is a class of drugs to treat diabetes mellitus and give patients more options in the treatment of type 2 diabetes. To investigate the use of DPP-4 inhibitors among type 2 diabetic outpatients at Can Tho central general hospital. A descriptive cross-sectional study was conducted in 108 patients with type 2 diabetes mellitus who had not reached the HbA1c target (HbA1c > 7%) and indicated DPP-4 inhibitors for the first time without changing the regimen for 3 months. Data were collected by from medical records. The most popular DPP-4 inhibitor prescribed was sitagliptin. Metformin was the most common oral hypoglycemic agents to be combined with DPP-4 inhibitors. After 3 months under treatment with DPP-4 inhibitors, blood glucose level reduced by 1,64 ± 1,59 mmol/L, HbA1c reduced by 1,52 ± 1,17% on average; 53,7% and 47,2% of the study population achieved blood glucose goal and HbA1c goal, respectively. The percentage of patients experiencing interactive application is primarily seen in 23.5% metformin and insulin. The use of DPP-4 inhibitors in patients with type 2 diabetes mellitus who had not reached the HbA1c goal was found to be effective. Although the change in blood glucose and HbA1c was significant, the proportion of patients reaching treatment goal were still below expectation.